Saturday 17 October 2026
Export ABCL’s income statement to Excel — free account
AbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.80
0.88
−6.94%
Follow ABCL
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 4 | 6 | 2 | 3 | 5 |
P/E ratio |
— | 5,890.00 | 5,890.00 | 53.87 | 26.00 | 16.95 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 27.48 | 10.51 | 5.57 | 43.57 | 29.91 | 13.60 |
Altman Z-Score |
— | — | — | 23.71 | 9.90 | 7.50 | 3.32 | 1.67 | 1.66 |
P/FCF ratio |
— | 755.12 | 755.12 | 799.05 | 21.19 | 13.22 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 0.31 | 11.03 | 9.41 | 9.92 | 6.46 | 5.62 | 4.67 |
P/Operating CF |
— | (2,371.65) | (2,371.65) | 5,012.52 | (235.96) | 87.51 | (84.49) | (107.80) | (29.40) |
Beneish M-Score |
— | — | — | 17.69 | (2.71) | (3.32) | 2.55 | (2.57) | (1.06) |
P/B ratio |
— | 1,287.81 | 1,287.81 | 7.71 | 3.84 | 2.19 | 1.44 | 0.82 | 1.06 |
Price to Tangible BV |
— | 1,287.81 | 1,287.81 | 9.37 | 4.75 | 2.57 | 1.68 | 0.89 | 1.16 |
EV/Sales |
— | 0.00 | 0.00 | 24.94 | 8.53 | 3.70 | 23.01 | 7.46 | 6.21 |
EV/EBITDA |
— | 0.00 | 0.00 | 35.87 | 14.43 | 7.20 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 370.33 | 370.33 | 256.30 | 13.08 | 6.48 | (19.94) | (1.98) | (3.55) |
EV/FCF |
— | 747.79 | 747.79 | 725.38 | 17.19 | 8.78 | (7.06) | (1.13) | (2.63) |
Quick Ratio |
— | 1.83 | 1.37 | 7.80 | 7.53 | 8.03 | 6.86 | 8.93 | 9.60 |
Current Ratio |
— | 2.50 | 1.60 | 7.86 | 7.70 | 8.67 | 7.33 | 9.81 | 11.32 |
Net Debt/EBITDA |
— | 260.87 | 1.81 | (3.68) | (3.37) | (3.65) | 3.81 | 2.99 | 2.97 |
Debt/Assets |
0.00% | 0.00% | 14.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.99 | 0.45 | 0.32 | 0.34 | 0.03 | 0.02 | 0.06 |
Operating CF/Net income |
— | 12.21 | (1.22) | 0.27 | 1.59 | 1.75 | 0.30 | 0.67 | 0.90 |
Capex/Depreciation |
— | (7.27) | (2.16) | (2.78) | (3.39) | (2.19) | (2.51) | (0.81) | (1.48) |
Interest Coverage |
— | (3.55) | (19.70) | 22.91 | 33.62 | 53.53 | — | — | — |
| — | 8.34% | (65.94%) | 20.43% | 16.53% | 14.03% | (12.27%) | (14.75%) | (14.47%) | |
| — | 0.00% | (18.83%) | 16.54% | 13.21% | 11.09% | (9.67%) | (11.43%) | (10.78%) | |
ROIC |
— | 0.00% | (41.89%) | 41.25% | 46.00% | 42.05% | (40.43%) | (48.52%) | (33.25%) |
Return on Tangible Assets |
— | 1.95% | (16.72%) | 11.69% | 16.67% | 14.10% | (14.07%) | (16.04%) | (13.41%) |
Average Days of Receivables |
— | 41.33 | 102.97 | 333.82 | 156.21 | 29.02 | 293.63 | 425.55 | 283.21 |
Research and Development Expense of Revenue |
— | 65.71% | 87.09% | 12.61% | 16.54% | 22.22% | 461.95% | 580.10% | 248.68% |
Selling, General and Administrative Expense of Revenue |
— | 32.42% | 34.55% | 6.76% | 13.00% | 13.75% | 197.71% | 296.50% | 110.79% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.04 | 0.15 | 0.15 | 0.12 | 0.11 | 0.07 | 0.06 |
Share Based Compensation of Revenue |
— | 6.96% | 7.66% | 3.60% | 8.17% | 10.19% | 168.79% | 234.39% | 74.26% |
Graham Net Nets |
— | 0.01 | 0.01 | 0.10 | 0.16 | 0.27 | 0.32 | 0.52 | 0.33 |
Graham Number |
— | 0.00 | 0.00 | 9.36 | 6.78 | 7.38 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | 0.02% | 0.02% | 1.86% | 3.85% | 5.90% | (9.08%) | (18.77%) | (14.33%) |
Free Cash Flow Yield |
— | 0.13% | 0.13% | 0.13% | 4.72% | 7.57% | (7.48%) | (22.04%) | (17.34%) |
Revenue per Share |
— | 0.06 | 0.08 | 1.46 | 1.36 | 1.70 | 0.13 | 0.10 | 0.25 |
Operating CF per Share |
— | 0.02 | 0.02 | 0.14 | 0.89 | 0.97 | (0.15) | (0.37) | (0.44) |
Capex per Share |
— | (0.04) | (0.03) | (0.09) | (0.21) | (0.25) | (0.27) | (0.27) | (0.14) |
Free Cash Flow per Share |
— | (0.01) | (0.01) | 0.05 | 0.68 | 0.72 | (0.42) | (0.64) | (0.58) |
Cash per Share |
— | 0.07 | 0.05 | 3.73 | 2.71 | 3.20 | 2.72 | 2.21 | 1.87 |
Shareholders Equity per Share |
— | 0.00 | 0.07 | 5.22 | 3.72 | 4.33 | 3.99 | 3.59 | 3.24 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 0.07 | 5.22 | 3.72 | 4.33 | 3.99 | 3.59 | 3.24 |
Free Cash Flow |
— | (1.74) | (1.30) | 8.02 | 186.13 | 204.70 | (121.38) | (186.95) | (174.07) |
Working Capital |
— | 9.00 | 4.75 | 709.84 | 809.12 | 907.17 | 752.97 | 674.76 | 663.93 |
Capital Expenditures |
— | (5.31) | (4.00) | (14.67) | (58.45) | (72.66) | (77.51) | (78.40) | (42.77) |
Net Current Asset Value |
— | 15.00 | (0.60) | 638.30 | 636.96 | 717.86 | 536.21 | 446.90 | 338.19 |
EV/EBIT |
— | 0.00 | 0.00 | 37.27 | 15.65 | 8.30 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.60 | 0.34 | 0.06 | 0.16 | 0.15 | 2.04 | 2.72 | 0.57 |
Price to Operating Income |
— | 0.00 | 0.00 | 41.06 | 19.29 | 12.49 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.12 | 0.22 | 0.29 | 0.15 | 0.15 | 0.11 | 0.28 | 0.07 |
Cash ROIC |
— | (12.44%) | (6.13%) | 0.56% | 10.49% | 9.54% | (6.26%) | (10.95%) | (11.41%) |
Accounts Receivable Turnover |
— | 4.42 | 5.43 | 2.15 | 2.01 | 4.87 | 1.10 | 0.90 | 1.63 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 2.00 | 2.14 | 108.26 | 186.91 | 99.58 | 34.59 | 32.10 | 45.95 |
Average Payables |
— | 2.50 | 2.29 | 11.39 | 26.11 | 42.26 | 51.04 | 52.29 | 52.89 |
Average Inventory |
— | — | — | — | — | 2.00 | — | — | — |
Average Assets |
— | 0.00 | 11.74 | 514.51 | 1,162.05 | 1,429.74 | 1,514.50 | 1,424.32 | 1,358.75 |
Average Common Equity |
— | 3.50 | 3.35 | 416.61 | 928.12 | 1,129.51 | 1,192.80 | 1,104.20 | 1,011.49 |
Columns are period end dates